Retevmo™ (selpercatinib) capsules

40 mg, 80 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

RETEVMO™ (selpercatinib): Dosing Considerations

Selpercatinib may be taken with or without food unless coadministered with a proton pump inhibitor.

Detailed Information

  • Selpercatinib doses should be separated by approximately 12 hours.

  • A missed dose of selpercatinib should not be made up within 6 hours of the next scheduled dose.

  • Selpercatinib capsules should be swallowed whole and should not be opened, crushed, or chewed.1

    • Lilly currently has no information available on the opening of the capsules and administering the content in liquids or food for administration (such as mixing in applesauce) or administration through a G-tube.

  • If vomiting occurs after taking a dose of selpercatinib, do not administer an additional dose. Take the next dose at the scheduled time.1

Selpercatinib is taken orally twice daily until disease progression or unacceptable toxicity. The recommended dose of selpercatinib based on actual body weight is detailed in Table 1.1

Table 1. Recommended Selpercatinib Dosage1

Patient Weighta

Recommended Dosage

<50 kg

120 mg orally twice daily

50 kg

160 mg orally twice daily

a Based on actual patient weight.

Enclosed Prescribing Information

RETEVMO™ (selpercatinib) capsules, for oral use, Lilly

References

1. Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Glossary

G-tube = gastrostomy tube

Lilly = Eli Lilly and Company

Date of Last Review: May 22, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical